---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-24-000015"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:27:29.499356+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Health Q4 revenue $556M, FY revenue $1.96B (+45%); net loss ($142M), adj EBITDA $194.7M (+84%)

## Summary
- Full year 2023 revenue of $1,963.9M, up 45% YoY; net loss of $(142.3)M (net loss margin -7.2%).
- Adjusted EBITDA of $194.7M, up 84% YoY; cash flow from operations of $142.6M.
- Q4 2023 revenue $556.1M, net loss $(41.4)M, adjusted EBITDA $48.1M (8.6% margin).
- Initial 2024 outlook: revenue growth ~25% at midpoint, consistent with long-term targets.
- Announced four new revenue agreements, including first comprehensive oncology bundle and first Performance Suite for advanced imaging.

## SEC filing metadata
- accession: 0001628908-24-000015
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/evh-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-24-000015
- JSON: https://secwatch.observer/filing/0001628908-24-000015.json
- Plain text: https://secwatch.observer/filing/0001628908-24-000015.txt

## Key facts
- Earnings Releases
  Evolent Health, Inc. updated its 2024 guidance (initiated).
  - Period: 2024
  - Guidance: initiated
  - Result: guidance update
  source text: Provides initial outlook for 2024 in line with long-term targets
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm
- Earnings Releases
  Evolent Health, Inc. reported the quarter and year ended December 31, 2023 results: revenue $556,055 thousand, $1,963,896 thousand, net income ($41,395) thousand, ($142,260) thousand.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $556,055 thousand, $1,963,896 thousand
  - Net income: ($41,395) thousand, ($142,260) thousand
  - Result: reported results
  source text: Evolent Announces Fourth Quarter and Full Year 2023 Results • Full year revenue of $1,963.9 million, 45% growth over 2022 • Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.